Oral Administration of a Chemically Modified Curcumin, TRB-N0224, Reduced Inflammatory Cytokines and Cartilage Erosion in a Rabbit ACL Transection Injury Model. (April 2021)

• Record Type: Journal Article
• Authors: Coury, Josephine R.; Nixon, Ryan; Collins, Melinda; Schwartz, John; Chahine, Nadeen O.; Grande, Daniel A.
• Is Part Of: Cartilage. Volume 12:Number 2(2021)
• Page Start: 251
• Page End: 262
• Publication Date: 2021-04
• Subjects: osteoarthritis -- chemically modified curcumin -- MMP inhibitors -- inflammation -- cytokines -- DMOAD; Cartilage -- Periodicals; 616.7
• DOI: 10.1177/1947603518815263
• Languages: English
• ISSNs: 1947-6035

Abstract

Objective: To evaluate the effects of TRB-N0224, a chemically modified curcumin (CMC) with zinc binding properties and improved pharmacokinetics, in a rabbit anterior cruciate ligament (ACL) transection injury–induced model of osteoarthritis (OA). Design: Thirty-eight skeletally mature New Zealand white rabbits were studied in 4 groups: a sham with arthrotomy ( n = 6), control with ACL transection ( n = 6), and 2 treatment groups with ACL transection and administration of TRB-N0224 at low (25 mg/kg/day) ( n = 13) and high (50 mg/kg/day) ( n = 13) doses. After euthanization at 12 weeks, outcomes were measured by post-necropsy gross morphology, biomechanics, and cartilage and synovium histology. Rabbit blood ELISA quantified cytokine and matrix metalloproteinase (MMP) concentrations at 0, 4, 8, and 12 weeks. Results: Both treatment doses had fewer distal femoral condyle erosive defects than the control; the low dose demonstrated a mean 78% decrease ( P < 0.01). Histologically, the low- and high-dose treatment groups had fewer cartilage pathologic changes and less severe synovitis than the control. CMC alone did not have a major effect on the biomechanics of healthy cartilage or cartilage in the ACL transection model, as demonstrated in 5 of the 6 measured properties/regions ( P < 0.05). ELISA results suggested that the key mediators of OA, (interleukin) IL-1β, IL-6, TNFα (tumor necrosis factor-α), MMP-9, and MMP-13, had decreased concentrations with TRB-N0224 treatment at different time points between weeks 4 to 12 ( P < 0.05). Conclusions: In the pathogenesis of OA, an imbalance exists between catabolic and anabolic mediators. These results suggest the potential of TRB-N0224 to modulate MMP and cytokine levels, slowing the macroscopic and histopathological progression of OA.